We require Asthmatics patients for a new study.
This study will be at least 4 visits to the unit, including a residential stay of up to 16 days and will spread over approx. 7 weeks.
A payment of up to £4820 will be made on completion of the study for your time, travel expenses and to compensate for any inconvenience.
We are looking for patients diagnosed with Idiopathic Pulmonary Fibrosis for a new study.
This study will include around 8 visits to the unit over approximately 10 weeks. This includes at least 2 screening visits (which may increase to 3 visits), 5 outpatients visits and a follow-up visit.
A payment of up to £2225 will be made on completion of the study for your time, and to compensate for any inconvenience. Travel expenses may be compensated separately.
We require COPD patients for a new study.
This study will require approximately 8 visits to the unit and will be spread over approximately 5 months.
A payment of up to £720 plus travel expenses, or up to £1340 plus travel expenses if you participate in a group which has additional blood samples taken, will be made on the completion of the study for your time, travel expenses and to compensate for any inconvenience.
We require asthmatic patients aged 18 to 65 for a new study. This study will be require approximately 8 visits to the unit and will be spread over approximately 19 weeks.
A payment of up to £870 will be made on completion of the study for your time, travel expenses and to compensate for any inconvenience.
We require Asthmatic patients for a new study.
This study will be approx. 5-6 visits to the unit including one 9 night stay and is spread over approx. 3-8 weeks.
Adequate compensation will be made on completion of the study. This is for your time, travel expenses and to compensate for any inconvenience.
We require COPD patients for a new study. This study will be approx. 14 visits to the unit and will spread over approx. 139 – 149 days (20-21 weeks).You will be financially compensated for your time, travel expenses and for any inconvenience.
You can feel proud in the knowledge that your participation will be helping us to develop new treatments for future generations. Your time and commitment is also recognised in the following ways:
The Medicines Evaluation Unit (MEU) is a leading specialist clinical research facility working with the pharmaceutical industry to identify potential new treatments for conditions such as Asthma, COPD, Cystic Fibrosis, Hypertension, Psoriasis. The wellbeing of our volunteers is always our first priority and we have an outstanding reputation within the industry for performing high quality clinical research complying with strict clinical trial legislation. We have successfully conducted over 360 clinical trials and this number continues to grow.
We are majority owned by the North West Lung Centre Charity and due to the unique way that we operate, all profits generated by us are then reinvested into the research of future treatments for respiratory diseases. We are located in our own purpose built state of the art facility on the grounds of Wythenshawe Hospital and employ a team of dedicated medical professionals who are committed to excellence.
Read what our volunteers have had to say about our facilities, staff and what its really like taking part in a clinical trial at the Medicines Evaluation Unit.
A leading specialist clinical research facility working with the pharmaceutical industry to identify potential new treatments for conditions such as Asthma, Bronchitis and Emphysema and now many more therapeutic areas.
We at the MEU want to deliver rewarding research to improve clinical care whilst also rewarding our volunteers for their continued support.
Contact us…
The Medicines Evaluation Unit
The Langley Building
Southmoor Road
Wythenshawe Hospital
Manchester
M23 9QZ
T: 0800 655 6553
E: recruitment@meu.org.uk
